Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037851 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
A Phase 2 study of Pulmonary Aspergillosis, sponsored by Pulmocide.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 19
- Study locations
NCT05037851 is a Phase 2 study of Pulmonary Aspergillosis that has completed, run by Pulmocide. The registered enrollment target is 102 participants. The trial reports 19 study locations across 10 states.
The verdict
NCT05037851, a Phase 2 study of Pulmonary Aspergillosis, has completed, sponsored by Pulmocide.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 19
- Study locations
Study Summary
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Opelconazole
Study Locations (19)
Texas
- Clinical Research Site - Dallas
- Clinical Research Site 1 - Houston
- Clinical Research Site 2 - Houston
- Clinical Research Site 3 - Houston
Pennsylvania
- Clinical Research Site - Philadelphia
- Clinical Research Site - Philadelphia
- Clinical Research Site - Pittsburgh
California
- Clinical Research Site - La Jolla
- Clinical Research Site - Los Angeles
Florida
- Clinical Research Site - Jacksonville
- Clinical Research Site - Tampa
New York
- Clinical Research Site - New York
- Clinical Research Site - The Bronx
Other
- Clinical Research Site - Edmonton
- Clinical Research Site - Toronto
Arizona
- Clinical Research Site - Phoenix
Illinois
- Clinical Research Site - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05037851
The ClinicalTrials.gov registry entry for NCT05037851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulmocide, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Aspergillosis appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT05037851 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Texas, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT05037851 about?
NCT05037851 is a clinical study titled "A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)". A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
What is the current status of trial NCT05037851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2021-11-19. Estimated completion is 2023-11-13.
What conditions does trial NCT05037851 study?
This clinical trial studies the following conditions: Pulmonary Aspergillosis.
What interventions are being tested in trial NCT05037851?
The interventions under investigation include: Standard of Care (DRUG), Opelconazole (DRUG).
Who is sponsoring clinical trial NCT05037851?
This trial is sponsored by Pulmocide, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037851 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.